Tyrosine hydroxylase deficiency: Clinical manifestations of catecholamine insufficiency in infancy

Movement Disorders

Volumn 17, Issue 2, 2002, Pages 354-359

  Grattan Smith, Padraic J ^a   Wevers, Ron A ^b   Steenbergen Spanjers, Gerry C ^b   Fung, Victor S C ^c   Earl, John ^a   Wilcken, Bridget ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

Dopamine; Epinepherine deficiency syndrome; Infantile parkinsonism; L dopa induced dyskinesia; Tyrosine hydroxylase deficiency

Indexed keywords

AMINE; BENSERAZIDE PLUS LEVODOPA; CATECHOLAMINE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVODOPA; NORADRENALIN; SELEGILINE; TYROSINE 3 MONOOXYGENASE;

AKINESIA; BRAIN DEVELOPMENT; CASE REPORT; CATECHOLAMINE INSUFFICIENCY; CATECHOLAMINE SYNTHESIS; CLINICAL FEATURE; CONSANGUINITY; DISEASE COURSE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DYSKINESIA; DYSTONIA; ENZYME DEFICIENCY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC DISORDER; HEMIBALLISM; HOMOZYGOSITY; HUMAN; INFANCY; INFANT; IRRITABILITY; METABOLIC DISORDER; MIOSIS; NEUROLOGIC DISEASE; OCULOGYRIC CRISIS; OROPHARYNX; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PTOSIS; REVIEW; RIGIDITY; SLEEP DISORDER; SYMPTOMATOLOGY; TREMOR; TYROSINE 3 MONOOXYGENASE DEFICIENCY; VOMITING;

CONSANGUINITY; DEVELOPMENTAL DISABILITIES; DOPAMINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LEVODOPA; NEUROLOGIC EXAMINATION; NOREPINEPHRINE; PARKINSONIAN DISORDERS; TREMOR; TYROSINE 3-MONOOXYGENASE;

EID: 0036523866     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10095     Document Type: Review

References (35)

1. Knappskog PM, Flatmark T, Mallet J, Ludecke B, Bartholome K. Recessively inherited L-dopa-responsive dystonia caused by a point mutation (Q381 K) in the tyrosine hydroxylase gene. Hum Molec Genet 1995;4:1209-1212.
2. Ludecke B, Knappskog PM, Clayton PT, et al. Recessively inherited L-dopa-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum Molec Genet 1996;5:1023-1028.
3. Wevers RA, De Rijk-van Andel JF, Brautigam C, et al. A review of biochemical and molecular genetic aspects of tyrosine hydroxylase deficiency including a novel mutation (291de1C). J Inher Metab Dis 1999;22:364-373.
4. Dionisi-Vici C, Hoffman GF, Leuzzi V, et al. Tyrosine hydroxylase deficiency with severe clinical course: Clinical and biochemical investigations and optimization of therapy. J Pediatr 2000;136: 560-562.
5. Swaans RJ, Rondot P, Renier WO, Van Den Heuvel LP, Steenbergen-Spanjers GC, Wevers RA. Four novel mutations in the tyrosine hydroxylase gene in patients with infantile parkinsonism. Ann Hum Genet 2000;64:25-31.
6. de Rijk-Van Andel JF. Gabreels FJ, Geurtz B, Steenbergen-Spanjers GC, van Den Heuvel LP, Smeitink JA, Wevers RA. L-dopa-responsive infantile hypokinetic rigid Parkinsonism due to tyrosine hydroxylase deficiency. Neurology 2000;55:1926-1928.
7. Hyland K, Fryburg JS, Wilson WG, Bebin EM, Arnold LA, Gunasekera RS. Jacobson RD, Rost-Ruffner E, Trugman JM. Oral phenylalanine loading in dopa-responsive dystonia: a possible diagnostic test. Neurology 1997;48:1290-1297.
8. Earl JW. Measurement of the acidic metabolites of biogenic amines. In: Sampson DC, editor. The clinical biochemist - monographs "HPLC in the clinical laboratory." Australasian Association of Clinical Biochemists; 1986:57-62.
9. van den Heuvel LP, Luiten B, Smeitink JA, de Rijk-van Andel JF, Hyland K, Steenbergen-Spanjers GC, Janssen RJ, Wevers RA. A common point mutation in the tyrosine hydroxylase gene in autosomal recessive L-dopa-responsive dystonia (DRD) in the Dutch population. Hum Genet 1998;102:644-646.
10. Zhou Q-Y, Quaife CJ, Palmiter RD. Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature 1995;374:640-646.
11. Hoffman GF, Surtees RAH, Wevers RA. Cerebrospinal fluid investigations for neurometabolic disorders. Neuropediatrics 1998; 29:59-71.
12. Factor SA, Coni RJ, Cowger M, Rosenblum EL. Paroxysmal tremor and orofacial dyskinesia secondary to a biopterin synthesis defect. Neurology 1991;41:930-932.
13. Snyderman SE, Sansaricq C, Pulmones MT. Successful long term therapy of biopterin deficiency. J Inher Metab Dis 1987;10:260-266.
14. Korenke GC, Christen HJ, Hyland K, Hunneman DH, Hanefeld F. Aromatic L-amino acid decarboxylase deficiency: an extrapyramidal movement disorder with oculogyric crises. Eur J Ped Neurol 1997;2/3:67-71
15. Surtees R, Clayton P. Infantile Parkinsonism-dystonia: tyrosine hydroxylase deficiency. Mov Disord 1998;13:350.
16. McAuley JH, Marsden CD. Physiological and pathological tremors and rhythmic central motor control. Brain 2000;123:1545-1567.
17. Steriade M, Gloor P, Llinas RR, Lopes de Silva FH, Mesulam MM. Report of IFCN Committee on Basic Mechanisms. Basic mechanisms of cerebral rhythmic activities. Electroencephalogr Clin Neurophysiol 1990;76:481-508.
18. Kellaway P. An orderly approach to visual analysis: characteristics of the normal EEG of adults and children. In: Daly D, Pedley TA, editors. Current practice of clinical electroencephalography 2nd ed. New York: Raven Press; 1990. p 184.
19. Furukawa Y, Kish SJ, Bebin EM, Jacobson RD, Fryburg JS, Wilson WG, Shimadzu M, Hyland K, Trugman JM. Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase I gene mutations. Ann Neurol 1998;44: 10-16.
20. Kim DS, Szozypka M, Palmiter RD. Dopamine-deficient mice are hypersensitive to dopamine receptior agonists. J Neurosci 2000; 20:4405-4413.
21. Rascol O. L-dopa-induced peak-dose dyskinesia in patients with Parkinson's disease: a clinical pharmocological approach. Mov Disord 1999;14(Suppl. 1):19-32.
22. Trinidad KS, Kurlan R. Chorea, athetosis, dystonia, tremor and Parkinsonism. In: Robertson M, Valsamma E, editors. Movement and allied disorders in childhood. Chicester: John Wiley and Sons; 1995. p 105-149.
23. Nygaard TG, Waran SP, Levine RA, et al. Dopa-responsive dystonia Simulating cerebral palsy. Pediatr Neurol 1994;11:263-240.
24. Furakawa Y, Graf WD, Wong H et al. Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations. Neurology 2001;56:260-263.
25. Greene P, Bressman S, Ford B, Hyland K. Parkinsonism. dystonia and hemiatrophy. Mov Disord 2000;15:537-541.
26. Hyland K, Surtees RAH, Rodeck C, Clayton PT. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 1992;42:1980-1988.
27. Maller A, Hyland K, Milstein S, et al. Aromatic L-amino Acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a second family. J Child Neurol 1997;12:349-354.
28. Swoboda KJ, Hyland K, Goldstein DS, et al. Clinical and therapeutic observations in aromatic L-amino acid decarboxylase deficiency. Neurology 1999;53:1205-1211.
29. Leigh RJ, Foley JM, Remler B, Civil RH. Oculogyric crisis: a syndrome of thought disorder and ocular deviation. Ann Neurol 1987;22:13-17.
30. Man in 't Veld AJ, Boomsma F, Moleman P, Schalekamp MA. Congenital dopamine-beta-hydroxylase deficiency. Lancet 1987;1: 183-187.
31. Biaggioni I, Goldstein D, Atkinson T, Robertson D. Dopamine-β-hydroxylase deficiency in humans. Neurology 1990;40:370-373.
32. Robertson D, Haile V, Perry SE, et al. Dopamine β-hydroxylase deficiency: a genetic disorder of cardiovascular regulation. Hypertension 1991;18:1-8.
33. Thomas SA, Marck BT, Palmiter RD, Matsumoto AM. Restoration of Norepinephrine and reversal of phenotypes in mice lacking dopamine B-hydroxylase. J Neurochem 1998;70:2468-2476.
34. Boghen D. Apraxia of eye lid opening: a review. Neurology 1997; 48:1491-1494
35. Dodd J, Role LW. The autonomic nervous system. In: Kandel ER, Schwartz JH, Jessel TM, editors. Principles of neural science 3rd ed. London: Appleton and Lange; 1991. p 761-777.